Results 21 to 30 of about 72,745 (302)

Health-Related Quality of Life in Patients with CVID Under Different Schedules of Immunoglobulin Administration: Prospective Multicenter Study [PDF]

, 2019
We assessed the health-related quality of life (HRQoL) in CVID adults receiving different schedules of immunoglobulin replacement therapy (IgRT) by intravenous (IVIG), subcutaneous (SCIG), and facilitated (fSCIG) preparations.
Agostini, Carlo, Bonanni, Livia, Carrabba, Maria, Cinetto, Francesco, Crescenzi, Ludovica, Fabio, Giovanna, Farrugia, Albert, Milito, Cinzia, Neri, Raffaella, Pecoraro, Antonio, Pulvirenti, Federica, Quinti, Isabella, Spadaro, Giuseppe, Tabolli, Stefano   +13 more
core   +2 more sources

Human inmmunoglobulin in primary immunodeficiencies

Acta Pediátrica de México, 2014
Human immunoglobulin replacement therapy has become a corner- stone in the treatment of patients with primary immunodeficiencies (PID). Currently indicated as first-line therapy for predominantly antibody deficiencies, severe combined immunodeficiencies,
Sheffler Mendoza Selma, Partida Gaytán Armando, Yamazaki Nakashimada Marco Antonio   +2 more
doaj   +1 more source

Primary vs. Secondary Antibody Deficiency: Clinical Features and Infection Outcomes of Immunoglobulin Replacement [PDF]

, 2014
Secondary antibody deficiency can occur as a result of haematological malignancies or certain medications, but not much is known about the clinical and immunological features of this group of patients as a whole. Here we describe a cohort of 167 patients
AA Bousfiha, B Gathmann, B Gathmann, B Piqueras, B Seymour, C Casulo, C Wehr, DF Florescu, E Becerra, E Castigli, ES Resnick, FA Bonilla, G Gunther, H Chapel, H Chapel, H Griffiths, Hilary J. Longhurst, HM Chapel, I De La Torre, I Quinti, J Blore, J Shortt, JA Freeman, JD Edgar, John Dempster, JS Orange, JS Orange, K Warnatz, K Warnatz, L Mouthon, Lorena Lorenzo, M Lucas, M Makatsori, M Yomota, Matthaios Speletas, Matthew Buckland, ME Conley, ME Rose, MJ Boumans, N Ozaras, N Venhoff, NH Yip, P Bright, P McLaughlin, P Wood, R Herriot, S Baris, S Bernatsky, S Molica, Sai S. Duraisingham, Sofia Grigoriadou, SS Duraisingham, T Kawano, U Salzer, W Al-Herz, W Strober   +55 more
core   +3 more sources

Successful discontinuation of immunoglobulin G replacement at age 10 in a patient with immunoglobulin G2 deficiency

SAGE Open Medical Case Reports, 2017
Context: Immunoglobulin G2 deficiency that persists beyond the age of 6 years is likely to be permanent. Case report: We report on a young Japanese female, diagnosed as having immunoglobulin G2 deficiency and low anti-pneumococcal immunoglobulin G2 ...
Masayoshi Shinjoh, Yukio Sakiyama, Shinichiro Sekiguchi, Takao Takahashi   +3 more
doaj   +1 more source

Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease

Frontiers in Immunology, 2021
ObjectiveTo evaluate the characteristics of patients with autoimmune disease with hypogammaglobulinemia following rituximab (RTX) and describe their long-term outcomes, including those who commenced immunoglobulin replacement therapy.MethodsPatients ...
Joanna Tieu, Joanna Tieu, Joanna Tieu, Rona M. Smith, Rona M. Smith, Seerapani Gopaluni, Seerapani Gopaluni, Dinakantha S. Kumararatne, Mark McClure, Mark McClure, Ania Manson, Sally Houghton, David R. W. Jayne, David R. W. Jayne   +13 more
doaj   +1 more source

Serum Free Light Chains Removal by HFR Hemodiafiltration in Patients with Multiple Myeloma and Acute Kidney Injury. a Case Series [PDF]

, 2018
Background/Aims: Multiple myeloma (MM) represents 10% of all haematologic malignancies. Renal involvement occurs in 50% of MM patients; of them, 12-20% have acute kidney injury (AKI), with 10% needing dialysis at presentation. While hemodialysis (HD) has
Antolino, Giusy, Festuccia, Francescaromana, Fofi, Claudia, Giammarioli, Elisa, La Verde, Giacinto, Mene, Paolo, Punzo, Giorgio, Tafuri, Agostino   +7 more
core   +2 more sources

Intravenous Immunoglobulins: Mechanism of Action and Limitations of Clinical Application in Pediatrics

Zdorovʹe Rebenka, 2016
This review deals with an analysis of the available clinical studies and reports concerning the evaluation of the effectiveness and safety of intravenous immunoglobulins (IVIG) in various diseases in children. Intravenous immunoglobulins are drugs with a
S.O. Mokiia-Serbina
doaj   +1 more source

Acute reduction in secretory immunoglobulin A following smoking cessation [PDF]

, 2004
Smokers report an increase in upper respiratory infections in the early phase of stopping smoking. One possible cause is a depletion in secretory immunoglobulin A (S-IgA) which has been observed in one study.
Clow, A, Evans, P, Hucklebridge, F, McEwen, B, Steptoe, A, Ussher, M, West, R   +6 more
core   +1 more source

Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients

Haematologica, 2014
Intravenous immunoglobulin replacement therapy represents the standard treatment for hypogammaglobulinemia secondary to B-cell lymphoproliferative disorders. Subcutaneous immunoglobulin infusion is an effective, safe and well-tolerated treatment approach
Nicolò Compagno, Francesco Cinetto, Gianpietro Semenzato, Carlo Agostini   +3 more
doaj   +1 more source

High throughput sequencing in acute lymphoblastic leukemia reveals clonal architecture of central nervous system and bone marrow compartments [PDF]

, 2017
No abstract ...
Adams, Stuart, Bartram, Jack, Brooks, Tony, Edwards, Darren, Goulden, Nick, Halsey, Christina, Hubank, Mike, Inglott, Sarah, Wright, Gary, Yousafzai, Yasar   +9 more
core   +3 more sources